Overview

Recent News

Date	Title and Summary
Toggle Summary May 08, 2019	Assertio Therapeutics Announces First-Quarter 2019 Financial Results -- Reports Neurology Franchise Net Sales of $26.3 million -- -- Commercialization Agreement Revenues of $30.9 million -- -- Raises 2019 Earnings Guidance Range and Confirms Neurology Franchise Net Sales Guidance -- -- Significant Debt Reduction -- LAKE FOREST, Ill.
Toggle Summary Apr 24, 2019	Assertio Therapeutics to Report First Quarter 2019 Financial Results After The Close of Markets on Wednesday, May 8, 2019 LAKE FOREST, Ill. , April 24, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release first quarter 2019 financial results on Wednesday, May 8, 2019 , after the close of markets. Following the announcement, the Company will host a conference call
Toggle Summary Apr 01, 2019	Assertio Therapeutics Announces Appointment of Jay Galeota to Board of Directors LAKE FOREST, Ill. , April 01, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) announced today that James (Jay) J. Galeota, Jr. has been appointed to the Company’s Board of Directors. Mr. Galeota most recently served as the President and Chief Operating Officer of G&W

Filing date	Description	Form	Filing Group	View
Aug 15, 2018	8-K12B	8-K12B	Other	View HTML 0001104659-18-052087.pdf 0001104659-18-052087.rtf 0001104659-18-052087.xls
Mar 29, 2002	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	Proxy Filings	View HTML 0000912057-02-012655.pdf 0000912057-02-012655.rtf 0000912057-02-012655.xls
Mar 25, 2015	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	Proxy Filings	View HTML 0001047469-15-002712.pdf 0001047469-15-002712.rtf 0001047469-15-002712.xls
Apr 05, 2016	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	Proxy Filings	View HTML 0001047469-16-011902.pdf 0001047469-16-011902.rtf 0001047469-16-011902.xls
Mar 16, 2018	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	Proxy Filings	View HTML 0001047469-18-001778.pdf 0001047469-18-001778.rtf 0001047469-18-001778.xls

Continental Stock Transfer & Trust Company
17 Battery Place, 8th Floor
New York, NY 10004
Phone: 800.509.5586
http://www.continentalstock.com

Ernst & Young LLP
Palo Alto, CA

John B. Thomas
SVP, Investor Relations & Corporate Communications
jthomas@assertiotx.com